Homocysteine enhances cytokine production in cultured synoviocytes from rheumatoid arthritis patients

P. E. Lazzerini¹, E. Selvi², S. Lorenzini², P. L. Capecchi¹, R. Ghittoni¹, S. Bisogno², M. Catenaccio², R. Marcolongo², M. Galeazzi², F. Laghi-Pasini¹

Department of Clinical Medicine and Immunological Sciences, ¹Division of Clinical Immunology, ²Division of Rheumatology, University of Siena, Italy.

Abstract

Objective

Hyperhomocysteinemia is commonly observed in Rheumatoid Arthritis (RA) patients, thus putatively accounting in part for the high rate of cardiovascular events in these subjects. Homocysteine (Hcy) is known to exert a pro-inflammatory effect putatively contributing to the progression of atherosclerotic lesions by cytokine production from several vascular cell-types.

In order to evaluate the possibility that Hcy may play a direct pro-inflammatory activity also in the joints of RA patients, we investigated: (i) the joint concentration of Hcy, and (ii) the effect of Hcy on cytokine production by unstimulated and IL-1β-stimulated human RA cultured synoviocytes.

Methods

In 5 RA and 5 controls subjects, Hcy was measured in the blood and knee synovial fluid, and specimens of synovial tissue were taken to obtain cell cultures. Cultures were incubated with Hcy (10-100 μmol/l) ± IL-1β, and IL-6 and IL-8 concentrations were evaluated in the supernatants (ELISA) together with the activation of nuclear factor-kB (NF-kB) (immunocytochemistry).

Results

Hcy was present in synovial fluids, with a mean concentration significantly higher in RA patients than in controls (9.0 ± 1.1 vs 5.9 ± 1.2 μmol/l). Hcy enhanced IL-6 and IL-8 production in RA synoviocytes only (up to 35%). Moreover, Hcy produced a clear-cut activation of NF-kB in rheumatoid cells only.

Conclusion

Hcy enhances IL-1-dependent cytokine production by rheumatoid synoviocytes at a concentration measurable in RA joints in vivo. Thus, in RA patients, Hcy may not only represent an important risk factor for the progression of cardiovascular diseases, but it may also contribute to the joint damage.

Key words

Homocysteine, rheumatoid arthritis, interleukin-6, interleukin-8, NF-kB, inflammation, synoviocytes.
Introduction
Mild hyperhomocysteinemia, as defined on the basis of plasma concentration ranging between 16-30 µmol/l, is an independent risk factor for coronary artery disease, cerebral and peripheral vascular disease (1-3), and for deep-vein thrombosis in the general population (4). Homocysteine-dependent vascular damage would be related to direct endothelial toxicity and indirect mechanisms, such as the induction of a prothrombotic state mediated by the effects on coagulation factors and platelets, and atherogenic modification of LDL. Moreover, recent data demonstrated that homocysteine (Hcy) is also provided with either immunomodulating and pro-inflammatory activities. More in detail, Hcy enhances the production of molecules such as IL-6, IL-8, and monocyte chemotactrant protein-1 by monocyte-macrophages and endothelial cells, and nitric oxide, matrix metalloproteinase-9 and vascular cell adhesion molecule-1 (VCAM-1) by vascular smooth muscle cells (5-9), thereby suggesting a possible additional role for Hcy in the inflammatory process supporting atherogenesis. These effects would be referred to an enhanced gene expression related to Hcy-induced activation of the nuclear factor kB (NF-kB), mediated by the production of superoxide anion (8-10). 

Materials and methods
Patient selection
Five patients with active RA were enrolled whose demography is depicted in Table I. All patients met the American College of Rheumatology 1987 revised criteria for rheumatoid arthritis (30). Active RA was defined as a European League Against Rheumatism Disease Activity Score in 28 joints (DAS28) of >3.2 (31). All the patients had an inflammatory knee joint involvement. Specimens of synovial tissue were obtained during diagnostic procedures for RA patients by needle biopsy. Before biopsy, synovial fluid was aspirated, and wet analysis by microscopy was performed to confirm the diagnosis. Before biopsy, synovial fluid leukocyte count was comprised between 2,000 and 10,000 cells/mm³. The control group (demography in Table I) was represented by five sex- and age-matched pa-
patients with osteoarthritis (OA) of the knee who underwent knee joint prosthesis; synovial fluid and synovial tissue specimens were obtained soon before and during joint replacement surgery, respectively. Also in this group, analysis of the synovial fluid by ordinary and polarised light microscopy was performed. Exclusion criteria were current infections or neoplasms. Oral informed consent was obtained in accordance with the Principles of the Declaration of Helsinki. All patients were under steroid treatment (mean daily dose < 8 mg of prednisone-equivalent) and/or nonsteroidal anti-inflammatory drugs. At the time of the study entry, patients were neither under disease modifying anti-rheumatic drugs, nor under TNFα-blocking therapy. More in detail, DMARDS treatment was discontinued at least 1 month before sample collection, for either inefficacy (2 patients), or occurrence of side effects (3 patients). The day of synovial sampling, blood was withdrawn from an antecubital vein and anticoagulated with sodium-citrate for the measurement of Hcy plasma levels.

**Homocysteine measurement in blood and synovial fluid**

Total Hcy was measured in plasma and synovial fluid using tri-n-butylphosphine and 7-thiouro-benzo-2-oxa-1,3-diazole-4-sulphamate. The derivatives were separated by reversed-phase high-performance liquid chromatography. In our laboratory and in the literature the normal control values for Hcy level in plasma range from 5 to 15 µm/l; no data are available in the literature about the level of Hcy in the synovial fluid.

**Synoviocyte cultures**

Immediately after sampling, 2 mm³ of synovial tissue from patients in both groups were removed in aseptic conditions and minced into 1 mm³ pieces. Synovial fragments were washed in saline solution (PBS, containing 200 U/ml penicillin and 200 µg/ml streptomycin) (Sigma-Aldrich, Milan, Italy). Synovial tissue was then digested by clostridial collagenase (Sigma-Aldrich, Milan, Italy) 1 mg/ml in PBS or in free serum Dulbecco’s Mod Eagle medium (DMEM, Invitrogen, Milan, Italy) containing the same concentration of antibiotics.

Collagenase digestion was carried out at 37°C for 24 hours with moderate stirring. The solution was then washed in saline solution and centrifugated for 10 minutes at 700 g. Cell suspensions were submitted to trypan blue vital stain (usually 90-95% of the cells recovered were alive).

Cell suspensions obtained were plated out in 2 ml of DMEM supplemented with L-glutamine (Sigma-Aldrich, Milan, Italy) (2 mM), foetal calf serum (FCS; Sigma-Aldrich, Milan, Italy) (10%), penicillin (200 U/ml) and streptomycin (200 µg/ml) in 35 mm²/tissue culture dish (Sarstedt, Nümbrecht, Deutschland) (35 x 10 mm² style) in humidified atmosphere containing 5% CO₂, and were grown to confluence two more times. We obtained 4 culture dishes (100 x 20 mm² style), with a final concentration of 1.5 x 10⁶ cells per dish.

The number of passages was carefully monitored in order to keep the cells well differentiated. Synovial fibroblasts were plated out in 400 ml of complete medium (DMEM without red phenol, supplemented with penicillin 200 U/ml, streptomycin 200 µg/ml, and 2.5% FCS) in 48-well tissue culture plate (1x10⁵ cells/well) and allowed to attach for 24 hours.

**Culture stimulation**

Culture medium was replaced with fresh complete medium containing DL-Hcy (10,20,50,100 µmol/l) (Sigma-Aldrich, Milan, Italy) with human recombinant IL-1β (0.1 ng/ml; Boehringer-Mannheim, Germany). The concentration of IL-1β employed is that commonly found in the synovial fluid of RA patients (32). After 8 and 24 hours of incubation, the supernatant was collected and stored at -20°C. The effect of DL-Hcy (10,20,50,100 µmol/l) alone was also evaluated in comparison with untreated cells, in the same experimental conditions after a 24h incubation. The effect of the vehicle PBS was also evaluated as a blank.

**Cytokine assay**

The concentration of immunoreactive IL-6 and IL-8 in culture supernatants was measured by a colorimetric sandwich ELISA kit (Euroclone Lugano, Switzerland). The concentration of the cytokines was expressed as ng/ml. Supernatants from each well were tested for cytokine assay in duplicate.

**Evaluation of NF-κB activation**

Cultured synoviocytes from two RA and two OA patients were immunostained for the NF-κB p65 subunit, i.e. the active form of the NF-κB, in basal condition, after 50 µmol/l Hcy incubation and after IL-1β incubation. Stimulated synoviocytes from patients were detached from culture plate by trypsin treatment, and then resuspended in PBS to a final concentration of 300 cells/µm². 100 µl of the cell suspension were centrifuged onto poly-L-lysine coated slides, air dried and 10 min fixed in precooled acetone. Slides were incubated 1 hour at 4°C with the anti-human mouse monoclonal IgG NF-κB p65 (Santa-Cruz Biotechnology California, USA) diluted 1:400 in PBS. Immunoreactions were then developed by using Vectastain ABC Kit (Vector Laboratories, Burlingame, CA USA) according to the data sheet specifications and stained by diaminobenzidine solution (Sigma-Aldrich, Milan, Italy).

**Cell viability**

Cell viability was evaluated after cell incubation with an increasing concentration of Hcy (10-100 µmol/l) in the culture medium for 48 hours by methylthiazoletetrazolium (MTT, Sigma-Aldrich, Milan, Italy) and trypan-blue exclusion test (33). The control culture was obtained by incubating cells with culture medium for 24 hours. Results were expressed as mean ± SD.

**Statistical analysis**

The difference in plasma and synovial fluid Hcy concentration between RA patients and controls, was estimated by
a two-tailed unpaired Student’s t test. Statistical evaluation of the effect of Hcy treatment ± IL-1β on RA- and control-derived synoviocytes was performed by the one-way analysis of variance for repeated measurements (RM-ANOVA) for normally distributed data, and by Friedman repeated measurements analysis of variance on ranks (RM-ANOVA on Ranks) for non-normally distributed data. Then a “post-hoc” test (Student-Newman-Keul’s test for multiple comparisons) was employed to compare the effects of the different treatments. The level of significance was set at P < 0.05.

Results

Synovial fluid analysis
Synovial fluid from osteoarthritis patients showed a typical “non-inflammatory pattern”, characterized by a transparent yellow coloured, viscous macroscopic appearance, whereas synovial fluid from RA patients showed an inflammatory pattern with reduction in viscosity and transparency. No crystals were detected by ordinary and polarised light microscopy in all the samples studied. The mean volume aspirated and the leukocyte count are reported in Table I.

Homocysteine level in blood and synovial fluid
Mean Hcy plasma level seemed slightly higher in RA patients than in controls, but the difference did not reach statistical significance (16.5 ± 2.1 vs 14.8 ± 2.4 μmol/l); on the contrary, mean Hcy concentration in the synovial fluid was significantly higher in patients with RA than in the controls (9.0 ± 1.1 vs 5.9 ± 1.2 μmol/l; p = 0.001). As a matter of fact, synovial/plasma Hcy ratio was higher in the RA than in the control group (0.54 vs 0.40) (Fig.1). On the basis of these findings, we stimulated synoviocyte cultures also with an Hcy concentration of 10 μmol/l to mimic the pathophysiological conditions really operating in vivo in RA patients.

Cytokine production
Co-incubation of Hcy and IL-1β was able to time- and dose-dependently enhance IL-6 production in cultured synoviocytes from RA patients (Table II). Conversely, no effect was observed on cultures from controls (Table II). The extent of IL-6 production was greater after 24 h (Table II) than it was after 8 h (Table II) cell incubation with Hcy+IL-1β. The maximal stimulating effect was reached with 20-50 μmol/l Hcy, after 8 and 24 h incubation. Interestingly, the increase in cytokine levels after incubation with 100 μmol/l Hcy was less relevant than that observed with 50 μmol/l Hcy (Tab. II). Indeed, it is remarkable that also 10 μmol/l Hcy was able to induce a significant cytokine increase after 24 h incubation (Table II).

A similar behaviour was observed in the production of IL-8 after 8 h (Table III) and 24 h (Table III) incubation with Hcy+IL-1β. The extent of the maximal stimulating effect of the co-incubation with Hcy+IL-1β with respect to IL-1β alone was over 30 percent for both cytokines (+32% for IL-6 and +36% for IL-8).

Synoviocytes produce a low amount of IL-6 and IL-8 (Table IV) in resting conditions, i.e., without co-incubation with IL-1β. Synoviocytes from RA patients produce slightly higher amounts of the cytokines than cells from controls (Table IV). In these experimental conditions, the addition of Hcy produced a significant stimulating effect on cytokine production only in synoviocytes from RA patients (Table IV).

NF-kB activation
On immunohistochemistry preparations, positive reactions for the NF-kB p-65 subunit were observed in all the slides from RA patients. Interestingly, a mild immunoreaction was present also in cytospin preparations from unstimulated rheumatoid synoviocytes, as an expression of a constitutive activation of NF-kB.

Table I. Demographic characteristics of patients. Data are expressed as mean ± SD [range].

<table>
<thead>
<tr>
<th></th>
<th>OA</th>
<th>RA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>62 ± 5 (58-71)</td>
<td>56 ± 8 (48-69)</td>
</tr>
<tr>
<td>Sex (n women/n men)</td>
<td>3/2</td>
<td>3/2</td>
</tr>
<tr>
<td>Disease duration (months)</td>
<td>72 ± 69 (10-110)</td>
<td>74 ± 38 (26-133)</td>
</tr>
<tr>
<td>DAS 28</td>
<td>-</td>
<td>4.1 ± 0.5 (3.6-5)</td>
</tr>
<tr>
<td>Synovial fluid leukocyte count (cell/mm³)</td>
<td>680 ± 430 (200-1300)</td>
<td>5500 ± 3200 (2000-9800)</td>
</tr>
<tr>
<td>Synovial fluid volume (ml)</td>
<td>22 ± 8 (15/35)</td>
<td>23 ± 6 (15/30)</td>
</tr>
<tr>
<td>ESR (mm/1st hour)</td>
<td>17 ± 3 (14/25)</td>
<td>51.9 ± 22 (35/81)</td>
</tr>
</tbody>
</table>

Fig. 1. Levels of Hcy in plasma and synovial fluid of rheumatoid arthritis (RA, n = 5) and osteoarthritis (controls; n = 5) patients. Student’s “t” test for unpaired data (RA vs controls). *** = p < 0.001.
of NF-κB. This condition markedly increased after Hcy incubation. However, as expected, IL-1β stimulation led to the most pronounced immunoreaction, since almost all the synoviocytes showed a strong immunostaining (Fig. 2). Conversely, in the slides from OA patients no immunoreactivity was observed under basal conditions, a mild reaction was detected after Hcy incubation. However, also in this case, a marked immunostaining was detected after stimulation with IL-1β (Fig. 2).

**Cell viability**

Hcy concentrations in the culture medium as high as 10, 20, and 50 μmol/l were associated with a cell viability > 90 %; at the 100 μmol/l Hcy concentration, cell viability was 83 ± 4 %.

**Discussion**

Mild hyperhomocysteinemia is an important risk factor for cardiovascular diseases and it is putatively involved in the development of the accelerated atherosclerosis associated with RA. Hcy promotes vascular damage also exerting a pro-inflammatory effect mediated by cytokine production from several cell-types implicated in the atherosclerotic process.

We investigated the possibility that in RA patients Hcy may represent not only a cardiovascular risk factor, but also an active mediator of the inflammatory process involved in the progression of joint damage. In this study, for the first time, we provide evidence that detectable amounts of Hcy are present in synovial fluids from RA and OA. Interestingly, we found that Hcy concentration in the synovial fluid from RA patients was significantly higher than that from control subjects with OA. In RA patients, higher synovial levels of Hcy suggest that the nature of the joint disease may influence Hcy intra-articular levels. A possible explanation for the phenomenon may consist in the increase in the blood in-flow and permeability in the synovial tissue due to the inflammatory condition of the joint in RA. However, we cannot rule out the possibility that an enhanced synthesis or deficient catabolism of Hcy take place intra-articularly in RA patients. Starting from these *ex-vivo* observations, we evaluated whether the higher levels of Hcy could influence the development
Pro-inflammatory activity of Hcy in RA joint / P.E. Lazzerini et al.

![Graph showing cytokine production](image)

**Fig. 2.** Cytospin preparations of synovial cells from RA and OA patients immunostained by anti-human mouse monoclonal IgG NF-κB p65. B: basal conditions, i.e. unstimulated cells; Hcy 50: with 50 μmol/l Hcy incubation; IL-1: with IL-1β 0.1 ng/ml stimulation.

The presence of co-stimulation with IL-1β from RA patients, particularly in the case of RA synoviocytes, leads to increased IL-6 and IL-8 production by synoviocytes, indicating that Hcy significantly enhances IL-6 production in RA synoviocytes. In accord with our hypothesis, we showed that Hcy significantly enhances IL-6 and IL-8 production by synoviocytes from RA patients, particularly in the presence of co-stimulation with IL-1β. The effect is described by a biphasic curve: an initial progressive increase in IL-6 and IL-8 levels for Hcy concentrations from 10 to 50 μmol/l, followed by a slight decline for Hcy concentration of 100 μmol/l. Conversely, no appreciable effect of Hcy on cytokine production from OA-derived cultured synoviocytes was detected. These findings suggest that RA synoviocytes bear peculiar features, partly related to a relevant and persistent inflammatory stimulation and/or genetic predisposition, with a non-specific pro-inflammatory attitude and a higher sensitivity to Hcy stimulation. It seems remarkable that the concomitant increase in both IL-6 and IL-8 induced by Hcy in our study, may putatively exert a cumulative effect on the pro-inflammatory process in vivo. Indeed, many studies clearly demonstrated the effectiveness of vitamin supplementation (mainly folate) in lowering Hcy plasma level in hyperhomocysteinemic subjects (36, 37), also affected with RA under methotrexate treatment, at least in adults (18, 38, 39). Folate supplementation is effective in reduce Hcy level also in patients not presenting evidence of vitamin deficiency (40). Conversely, no data are presently available on the possible reducing effect of such vitamins on synovial Hcy concentration. Since the present study seems to suggest a relationship between plasma and synovial Hcy levels, it seems conceivable that folate treatment may influence also homocysteine concentration in the joints.

At this moment, the observation that a higher Hcy concentration (> 50 μmol/l) exerts less potent effect on cytokine production has not a clear explanation. In fact, the data on cell viability suggest that some toxic effects occur at that Hcy concentration, responsible for a synoviocyte loss of about 17%. However, a dual concentration-dependent effect of Hcy on cytokine production cannot be ruled out, with a stimulating activity at low-medium concentration, and an inhibitory activity at high concentration.

Our data seems to suggest that, in patients affected with RA, Hcy may represent not only an important risk factor for the development of cardiovascular disease, but also a factor actively involved in the progression of joint damage. This conclusion is particularly supported by the observation that in our study the stimulating effect on cytokine production occurs for Hcy and IL-1β concentrations measured in RA joints in vivo.

As a consequence, the preservation of normal plasma level of Hcy in patients with RA may become a crucial goal in order to affect not only the accelerating systemic cardiovascular involvement, but also the immuno-inflammatory load sustaining the destroying effect of the disease on the joints. Indeed, many studies clearly demonstrated the effectiveness of vitamin supplementation (mainly folate) in lowering Hcy plasma level in hyperhomocysteinemic subjects (36, 37), also affected with RA under methotrexate treatment, at least in adults (18, 38, 39). Folate supplementation is effective in reducing Hcy level also in patients not presenting evidence of vitamin deficiency (40). Conversely, no data are presently available on the possible reducing effect of such vitamins on synovial Hcy concentration. Since the present study seems to suggest a relationship between plasma and synovial Hcy levels, it seems conceivable that folate treatment may influence also homocysteine concentration in the joints.

On this basis, a study aiming at evaluating the possible concomitant modifications of Hcy level in the blood and in the synovial fluid in RA patients after the onset of folate therapy is now in progress. The expected results of this study and the data obtained from the present work may strengthen the rationale for the addition of folate to the standard therapeutic regimen in all RA patients with hyperhomocysteinemia. Such a consideration seems to be of particular relevance in European countries, in which bread and cereals are universally supplemented with folate in North America.
ca, thus leading to lower mean plasma levels of Hey in the whole population.

References


